Chapter 21 — Mitral Stenosis

📚 Guideline basis

Baumgartner H, et al. EACVI/ASE Focused Update on Valve Stenosis (JASE 2017;30:372–92); 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease (Eur Heart J 2025;46:4635–); Wilkins et al. scoring for balloon valvuloplasty suitability; ASE 2025 diastolic update (mitral stenosis and mitral annular calcification sections).

Pathophysiology & Mechanisms

Mitral stenosis obstructs LV inflow. The consequences propagate backwards, and the ventricle itself is typically normal.

Elevated left atrial pressure is required to drive flow across the restricted orifice. The transmitral gradient is the pathology, not a marker of it.
Pulmonary venous and capillary hypertension follow passively, producing dyspnoea and, at high pressures, alveolar oedema and haemoptysis.
Reactive pulmonary arterial vasoconstriction and remodelling occur in a subset, converting a purely post-capillary problem into combined pre- and post-capillary pulmonary hypertension with a pressure load the RV cannot sustain. RV failure and secondary tricuspid regurgitation follow.
Left atrial dilatation predisposes to atrial fibrillation, stasis, and thromboembolism — the risk of which in rheumatic MS is high enough that anticoagulation is indicated regardless of CHA₂DS₂-VASc score.

The rate dependence that dominates ICU management

Transmitral flow occurs only during diastole. Since mean gradient scales with the square of flow rate and diastolic filling time falls steeply with heart rate:

ΔP(mean) ∝ (SV / t_diastole)²

Tachycardia is the single most potent aggravator of mitral stenosis. A patient stable at 70/min can develop pulmonary oedema at 130/min with an unchanged valve. This makes fever, sepsis, pain, hypovolaemia, and new atrial fibrillation the common precipitants of ICU decompensation, and it makes rate control a haemodynamic intervention rather than an arrhythmia intervention. Loss of atrial contraction compounds the problem.

Correspondingly, the fixed obstruction means the ventricle cannot increase output on demand. MS patients tolerate the increased cardiac output requirements of sepsis, pregnancy, and anaemia poorly.

Aetiology

Aetiology	Morphology	Notes
Rheumatic	Commissural fusion, leaflet thickening, chordal shortening and fusion; "hockey-stick" doming of the anterior leaflet in diastole because the tip is tethered while the body remains mobile	Still the dominant global cause; commissural fusion is what makes balloon valvuloplasty possible
Degenerative / mitral annular calcification	Calcification extends from the annulus into the leaflet bases; no commissural fusion; the orifice narrows from the base inward	Increasingly common in elderly and dialysis populations; not amenable to balloon valvuloplasty; quantification is unreliable
Radiation	Diffuse leaflet and annular thickening, often with aortic involvement	Prior mediastinal radiotherapy
Congenital, cor triatriatum, large LA myxoma	Inflow obstruction without valve disease	Consider in a young patient with "MS physiology"
Prosthetic obstruction	See Chapter 23

The distinction between rheumatic and MAC-related MS is the single most important morphological judgement, because it determines whether percutaneous therapy is possible at all.

Diagnostic Synthesis

Severity criteria

Parameter	Progressive	Severe	Very severe
Mitral valve area, cm²	> 1.5	≤ 1.5	≤ 1.0
Mean gradient, mmHg (at HR 60–80)	< 5	5–10	> 10
PASP, mmHg	< 30	30–50	> 50
Diastolic pressure half-time, ms	< 150	≥ 150	≥ 220

Valve area, not gradient, defines severity. Gradient is flow- and rate-dependent and is a supportive parameter only. This is stated explicitly in the 2017 EACVI/ASE document and carried into the 2025 ESC/EACTS guidelines.

The three methods for valve area

Method	Formula / technique	Strengths	Fails when
2D planimetry	Direct tracing of the smallest orifice in PSAX at the leaflet tips, in mid-diastole, at optimal gain	The reference method; independent of flow, rate, rhythm, and coexisting lesions	Poor image quality; heavy calcification; incorrect plane (too basal overestimates the area); after commissurotomy
Pressure half-time	`MVA = 220 / PHT`; note `PHT = 0.29 × DT`	Fast, feasible with poor 2D images	Invalid in most ICU patients — see below
Continuity equation	`MVA = (CSA_LVOT × VTI_LVOT) / VTI_MV`	Independent of chamber compliance	Invalid with significant MR or AR
PISA	`MVA = (2πr² V_a / V_peak MV) × (α/180)`, where α is the leaflet inflow angle	Useful when other methods fail	Angle correction is operator-dependent

Why pressure half-time fails in the ICU

PHT measures the rate at which the LA–LV pressure gradient dissipates. That rate depends on the orifice area and on the compliance of both chambers and the pressures within them. It is invalidated by:

Tachycardia — E and A fusion makes the deceleration slope unmeasurable
Atrial fibrillation — beat-to-beat variability
Significant aortic regurgitation — the AR jet raises LVEDP rapidly, shortening PHT and overestimating the valve area (making severe MS look moderate)
Reduced LV compliance — any stiff ventricle shortens PHT
Immediately after balloon valvuloplasty — acute compliance changes make PHT unreliable for 24–72 hours
Prosthetic valves — PHT systematically overestimates EOA (ASE 2024)

Since tachycardia, AF, and reduced LV compliance are the norm in critical illness, planimetry should be the default ICU method, with PHT used only as corroboration when the 2D image is adequate and the rhythm is regular.

Supporting findings

Left atrial dilatation (often severe), spontaneous echo contrast ("smoke") indicating stasis, left atrial appendage thrombus (requires TEE to exclude), pulmonary hypertension with RV pressure overload, secondary tricuspid regurgitation, and a normal-sized, normally contracting left ventricle.

Wilkins score — suitability for percutaneous balloon mitral valvuloplasty

Four components, each scored 1–4 (total 4–16):

Component	Score 1	Score 4
Leaflet mobility	Highly mobile, only tips restricted	No or minimal forward motion in diastole
Leaflet thickening	Near normal (4–5 mm)	Marked thickening throughout (8–10 mm)
Subvalvular thickening	Minimal, just below the leaflets	Extensive chordal thickening to the papillary muscles
Calcification	Single area of increased brightness	Extensive brightness through much of the leaflet tissue

Total ≤ 8 predicts a favourable valvuloplasty result. Absolute contraindications independent of the score: left atrial thrombus and more than mild mitral regurgitation. Bicommissural calcification also predicts a poor outcome.

ICU-Specific Limitations

Confounder	Effect	Response
Tachycardia	Mean gradient rises steeply; PHT unmeasurable with E–A fusion	Report heart rate with every gradient; use planimetry; rate control is treatment
Atrial fibrillation	Gradient and PHT vary 30–50% beat to beat	Average ≥ 5–10 beats; planimetry preferred
High output (sepsis, anaemia, pregnancy)	Gradient rises at unchanged area	Grade by area, not gradient
Coexisting AR	Shortens PHT, overestimating MVA	Planimetry or continuity
Coexisting MR	Invalidates the continuity equation	Planimetry
Mitral annular calcification	Planimetry and PHT both unreliable; no commissural fusion to split	Report descriptively; involve the Heart Team
Poor windows / prosthesis	TTE inadequate	TEE — also required for LA appendage thrombus

The ASE 2025 diastolic guideline notes that in mitral stenosis, elevated LA pressure is indicated by IVRT < 60 ms, mitral A velocity > 1.5 m/s, and IVRT/T(E-e′) < 4.2, and that E/e′ is not useful in this population.

Therapeutic Logic

Goal	Rationale	Practical
Rate control (60–80/min)	Lengthens diastolic filling time; the highest-yield single intervention	Beta-blockade or non-dihydropyridine calcium channel blockade; digoxin in AF; treat fever, pain and agitation
Restore sinus rhythm	Restores the atrial contribution and slows the rate	Cardioversion for new AF with decompensation; anticoagulate — TEE for LA appendage thrombus if not urgently unstable
Anticoagulate	High thromboembolic risk in rheumatic MS with AF, regardless of CHA₂DS₂-VASc	Vitamin K antagonist — DOACs are not established in rheumatic MS with AF
Careful volume management	Preload is needed to drive flow across the orifice, but excess raises LA pressure	Cautious diuresis for pulmonary oedema; avoid over-diuresis, which drops output
Avoid inotropes as a reflex	The LV is not the problem; inotropes cause tachycardia, which worsens the gradient	Address rate and rhythm first
Treat the precipitant	Sepsis, anaemia, pregnancy and thyrotoxicosis decompensate MS via output demand	Source control, transfusion, rate control
Definitive relief	Fixed obstruction	Emergency balloon valvuloplasty in refractory decompensation with a favourable score; surgery otherwise

🛑 Critical pitfall: Reporting a mean gradient without the heart rate. A gradient of 12 mmHg at 130/min and at 65/min describe entirely different valves.

🛑 Critical pitfall: Using pressure half-time in a tachycardic, fibrillating patient, or in one with coexisting aortic regurgitation. All three shorten PHT and make severe MS appear moderate.

🛑 Critical pitfall: Treating the hypotension of decompensated MS with fluid and inotropes. Both raise heart rate or left atrial pressure. Slow the rate, restore sinus rhythm, and treat the precipitant.

💡 Clinical pearl: Planimetry in the parasternal short axis at the leaflet tips is the most robust ICU method. Sweep from base to tip and take the smallest orifice; a plane taken too basally overestimates the area.
💡 Clinical pearl: Commissural fusion with a mobile leaflet body and a tethered tip — the hockey-stick sign — identifies rheumatic disease and therefore a valve that can potentially be split. Its absence in a calcified valve means valvuloplasty is not an option.
💡 Clinical pearl: New atrial fibrillation in a patient with previously compensated mitral stenosis is a haemodynamic emergency, not simply a rhythm problem.

References

Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of valve stenosis: EACVI/ASE focused update. J Am Soc Echocardiogr 2017;30:372–92.
ESC/EACTS. 2025 Guidelines for the management of valvular heart disease. Eur Heart J 2025;46:4635–.
Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60:299–308.
Nagueh SF, Sanborn DY, Oh JK, et al. ASE 2025 diastolic function update. J Am Soc Echocardiogr 2025;38:537–69.